SCHEMBL2655510

SCHEMBL2655510

CCN1Cc2nc3c(-c4cccc(OC)c4F)cccc3c(N)c2C1=O

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ PDE5A O76074 5/20 0.41
▸ METAP2 P50579 1/20 0.38
▸ GABRG2 P18507 3/20 0.38
▸ GABRB3 P28472 3/20 0.38
▸ GABRA2 P47869 3/20 0.38
▸ GABRA1 P14867 1/20 0.38
▸ GABRA5 P31644 1/20 0.38
▸ GABRA3 P34903 1/20 0.38
▸ GNRHR P30968 1/20 0.35
▸ PDE6C P51160 1/20 0.35
▸ UGCG Q16739 1/20 0.34
▸ DYRK1A Q13627 1/20 0.34
▸ FGFR1 P11362 1/20 0.34
▸ FGFR2 P21802 1/20 0.34
▸ BACE1 P56817 1/20 0.34
▸ ADORA2A P29274 3/20 0.33
▸ RPS6KA2 Q15349 1/20 0.33
▸ ACHE P22303 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4913419 0.92 GABRG2 (0.39) PDE5AMETAP2GABRG2GABRB3GABRA2
SCHEMBL2661396 0.91 PDE5A (0.43) PDE5AGABRG2GABRB3GABRA2GABRA1
SCHEMBL2655165 0.91 PDE5A (0.43) PDE5AGABRG2GABRB3GABRA2GABRA1
SCHEMBL2657124 0.91 PDE5A (0.41) PDE5AMETAP2GABRG2GABRB3GABRA2
SCHEMBL2661341 0.91 GABRG2 (0.38) PDE5AMETAP2GABRG2GABRB3GABRA2
SCHEMBL4919706 0.90 GABRA1 (0.49) PDE5AGABRG2GABRB3GABRA2GABRA1
SCHEMBL2661407 0.90 PDE5A (0.41) PDE5AGABRG2GABRB3GABRA2GABRA1
SCHEMBL2656734 0.88 BACE1 (0.38) METAP2GABRG2GABRB3GABRA2GABRA1
SCHEMBL4923506 0.87 PDE5A (0.37) PDE5AGABRG2GABRB3GABRA2GABRA1
SCHEMBL2661184 0.87 KDM4E (0.39) PDE5AGABRG2GABRB3GABRA2GNRHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US claimed
EP-2176263-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS AstraZeneca AB (SE) 2010-04-21 — — EP disclosed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US disclosed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US disclosed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US disclosed
WO-2008155572-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS ASTRAZENECA AB (SE) 2008-12-24 — — WO disclosed
WO-2008155572-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS ASTRAZENECA AB (SE) 2008-12-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080318943-A1 Compounds and Uses Thereof - 848 COMT, BACE1, BDNF PDE5A 742/4885METAP2 1585/4885GABRG2 592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback